Principles of early drug discovery

Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12–15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.

[1]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[2]  S. Rees,et al.  Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells. , 2000, Methods in enzymology.

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[4]  K Moore,et al.  Cell-Based Versus Isolated Target Screening: How Lucky Do You Feel? , 2001, Journal of biomolecular screening.

[5]  Philip M Dean,et al.  Probes for chemical genomics by design. , 2002, Drug discovery today.

[6]  J. Wyatt,et al.  Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats , 2002, PAIN.

[7]  N. Peet.  What constitutes target validation , 2003 .

[8]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[9]  T. Magnuson,et al.  Ablation of MEKK4 Kinase Activity Causes Neurulation and Skeletal Patterning Defects in the Mouse Embryo , 2005, Molecular and Cellular Biology.

[10]  P. Anand,et al.  Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain , 2005, Pain.

[11]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[12]  Sandra Fox,et al.  High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.

[13]  G. Ugolini,et al.  The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain , 2007, Proceedings of the National Academy of Sciences.

[14]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[15]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[16]  Y. Iba,et al.  Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Kiran Boppana,et al.  Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. , 2009, European journal of medicinal chemistry.

[18]  S. Rees,et al.  Use of primary human cells in high-throughput screens. , 2009, Methods in molecular biology.

[19]  Yongliang Yang,et al.  Target discovery from data mining approaches. , 2009, Drug discovery today.

[20]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[21]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[22]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[23]  J. Frearson,et al.  HTS and hit finding in academia – from chemical genomics to drug discovery , 2009, Drug discovery today.

[24]  Ted M. Lakowski,et al.  Approaches to measuring the activities of protein arginine N-methyltransferases. , 2010, Analytical biochemistry.

[25]  Elisa Michelini,et al.  Cell-based assays: fuelling drug discovery , 2010, Analytical and bioanalytical chemistry.